Update: June 2023
ACH |
Air change per hour |
AFB |
Acid-fast bacilli |
ALT | Alanine aminotransferase |
Am |
Amikacin |
Amx/Clv |
Amoxicillin/clavulanic acid |
ART |
Antiretroviral therapy |
ARV |
Antiretroviral |
AST | Aspartate aminotransferase |
BCG |
Bacillus Calmette-Guérin |
Bdq |
Bedaquiline |
BPNS | Brief peripheral neuropathy screen |
BSC | Biosafety cabinet |
CDC |
Centers for Disease Control and Prevention |
Cfz |
Clofazimine |
CrCl |
Creatinine clearance |
CMX |
Cotrimoxazole |
CNS | Central nervous system |
CPC |
Cetylpyridinum chloride |
CPT |
Cotrimoxazole preventive therapy |
Cs |
Cycloserine |
CSF | Cerebrospinal fuid |
CXR |
Chest x-ray |
Dlm | Delamanid |
DOT |
Directly observed therapy |
DR |
Drug resistance |
DR-TB |
Drug-resistant tuberculosis |
DS-TB | Drug-susceptible tuberculosis |
DST |
Drug susceptibility test |
E |
Ethambutol |
ECG |
Electrocardiogram |
EPTB |
Extrapulmonary tuberculosis |
Eto |
Ethionamide |
FDC |
Fixed-dose combination |
FNA |
Fine needle aspiration |
FQ |
Fluoroquinolone |
gDST | Genotypic drug susceptibility test |
GUV | Germicidal ultraviolets |
H |
Isoniazid (standard dose) |
HbA1c | Glycated haemoglobin |
Hh | Isoniazid (high dose) |
HIV |
Human immunodeficiency virus |
HPF |
High-power field |
Hr | Isoniazid resistance |
Hr-TB | Isoniazid resistant tuberculosis |
IGRA |
Interferon gamma release assay |
IPC |
Infection prevention and control |
IM |
Intramuscular |
Imp/Cln |
Imipenem/cilastatin |
INI | Integrase inhibitor |
IRIS |
Immune reconstitution inflammatory syndrome |
IV | Intravenous |
LF-LAM | Lateral flow urine lipoarabinomannan assay |
LFT |
Liver function test |
Lfx |
Levofloxacin |
LPA |
Line probe assay |
LTBI | Latent tuberculosis infection |
LTR | Long treatment regimen |
Lzd |
Linezolid |
MDR |
Multidrug resistance |
MDR-TB |
Multidrug-resistant tuberculosis |
Mfx |
Moxifloxacin (standard dose) |
Mfxh |
Moxifloxacin (high dose) |
Mpm |
Meropenem |
MTB | Mycobacterium tuberculosis |
NAAT | Nucleic acid amplification test |
NGS | Next generation sequencing |
NNRTI |
Non-nucleoside reverse transcriptase inhibitor |
NRTI |
Nucleoside reverse transcriptase inhibitor |
P | Rifapentine |
Pa | Pretomanid |
PAS |
Para-aminosalicylic acid |
PCP |
Pneumocystosis |
PCR |
Polymerase chain reaction |
pDST | Phenotypic drug susceptibility test |
PI |
Protease inhibitor |
PO |
Orally (per os) |
PTB | Pulmonary tuberculosis |
Pto |
Prothionamide |
R |
Rifampicin |
Rfb |
Rifabutin |
RMT | Rapid molecular test |
RR |
Rifampicin resistance |
S |
Streptomycin |
SAT | Self-administered treatment |
STR | Short treatment regimen |
TB |
Tuberculosis |
tNGS | Targeted next generation sequencing |
Trd | Terizidone |
TSH |
Thyroid-stimulating hormone |
TST |
Tuberculin skin test |
ULN | Upper limit of normal |
VVS | Ventilated workstation |
WGS | Whole genome sequencing |
WHO |
World Health Organization |
XDR |
Extensive drug resistance |
XDR-TB |
Extensively drug-resistant tuberculosis |
Z |
Pyrazinamide |